Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – ...
AB-1009 is an investigational gene therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated. For more information, ...
Pickup Truck Talk + SUV on MSN
New GM cylinder deactivation patent filing fixes reliability woes?– Coming for next-gen V8 engines
A recently filed patent details a new GM cylinder deactivation system that appears to be heading to the next-gen V8 engines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback